Celtaxsys, a clinical stage drug development company, has received a development award for $5 million from Cystic Fibrosis Foundation Therapeutics Inc, according to the company.
The development award will help support a Phase 2 clinical trial of the Celtaxsys’s lead development candidate, a once daily, oral anti-inflammatory drug CTX-4430 in adults with cystic fibrosis.
CTX-4430 is a selective inhibitor of Leukotriene A4 Hydrolase that targets re-balancing of a patient’s over activated inflammatory response without increasing susceptibility to infection. CTX-4430 has been granted orphan status for CF in both the US and the EU.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management
- Edition Archive